TABLE 3.

Relative hazards of cardiovascular outcomes associated with pre-transplant and transplant-related therapeutic exposures.^*

Exposure	Hazard ratio (95% CI)
	Cardiovascular death		Ischemic heart disease		Cardiomyopathy /heart failure		Stroke
Anthracycline†, mg/m2
None	1.0	(ref)	1.0	(ref)	1.0	(ref)	1.0	(ref)
<200	2.2	(0.7–7.6)	1.0	(0.4–2.5)	2.3	(0.8–6.8)	1.6	(0.5–4.6)
200–299	3.6	(0.9–14.1)	1.2	(0.3–4.1)	3.3	(0.8–13.2)	0.9	(0.2–4.4)
≤300	2.8	(0.9–8.8)	0.8	(0.3–.2)	4.5	(1.5–13.3)	2.2	(0.7–7.2)
Brain radiotherapy vs. none‡	1.1	(0.1–9.8)	-	0.7	(0.1–6.2)	0.7	(0.1–4.2)
Abdomen radiotherapy vs. none‡	2.7	(0.9–8.3)	1.8	(0.7–4.5)	0.8	(0.3–2.4)	0.9	(0.2–3.3)
Cardiac radiotherapy dose, Gy§
<1	1.0	(ref)	1.0	(ref)	1.0	(ref)	1.0	(ref)
1–19	0.3	(0.1–1.3)	0.6	(0.2–1.7)	0.9	(0.4–2.1)	0.6	(0.2–2.1)
≥20	1.4	(0.4–5.3)	1.3	(0.3–5.0)	1.3	(0.4–4.7)	0.5	(0.1–5.1)
Total body irradiation ≥10 Gy vs. less	1.4	(0.3–6.9)	1.7	(0.5–5.3)	1.2	(0.5–2.8)	1.0	(0.2–3.6)
Allogeneic vs. autologous donor	1.9	(0.5–7.7)	0.6	(0.2–2.2)	1.2	(0.4–3.4)	1.3	(0.3–5.5)
Chronic graft vs. host disease
None	1.0	(ref)	1.0	(ref)	1.0	(ref)	1.0	(ref)
Active	4.0	(1.1–14.7)	2.6	(0.7–8.9)	1.1	(0.4–3.1)	1.7	(0.4–7.0)
Resolved	1.2	(0.3–4.8)	2.2	(0.8–6.1)	1.4	(0.5–3.9)	1.4	(0.4–5.2)
Original disease relapse vs. none	4.3	(1.9–9.6)	1.5	(0.7–.2)	3.2	(1.7–6.0)	5.9	(2.4–14.7)

^*Estimates reflect adjustment for exposures shown plus sex, age at and year of transplant, and race/ethnicity.

^†In terms of doxorubicin equivalent dose.

^‡Brain and abdomen (including pelvis) fields exclusive of total body irradiation.

^§Inclusive of any total body irradiation.